Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Philip Morris International Inc.

www.pmi.com

Latest From Philip Morris International Inc.

Deals of the Week: Is Botox On The Block?

A pair of setbacks have sent Allergan’s stock price south, but will a buyer take advantage and buy it in a mega-deal? Also, Amgen and Servier team up in a CV deal, Forma pursues an asset-focused strategy in tandem with Cancer Research Technology, and Immunocore reveals an antibody deal with GSK.

BioPharmaceutical North America

Mitsubishi Tanabe Acquires Vaccine Development Partner Medicago

The Japanese firm hopes to broaden its domestic vaccine presence globally, while gaining virus-like particle technology in the deal to widen its therapeutic targets.

BioPharmaceutical Japan

Mitsubishi Tanabe Acquires Vaccine Development Partner Medicago

The Japanese firm hopes to broaden its domestic vaccine presence globally and gains virus-like particle technology in the deal to widen its therapeutic targets.

BioPharmaceutical Japan

Deals Shaping The Medical Industry, November 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Diversified
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Philip Morris International Inc.
  • Senior Management
  • Louis C Camilleri , Chmn. & CEO
    Hermann Waldemer, CFO
    Doug Dean, SVP, R&D
  • Contact Info
  • Philip Morris International Inc.
    Phone: (917) 663-2233
    120 Park Ave.
    New York, NY 10017
    USA
UsernamePublicRestriction

Register